This technology is currently being marketed with annual worldwide sales in excess of $1bn.
Raghav Chari, senior vice president of proprietary products business at Dr Reddy's, said: "We are extremely pleased to be working with Aegis and gaining access to their patented Intravail drug delivery technologies. The results of successful human studies completed to date will provide a unique product offering, satisfying a significant unmet need in the market. We hope this will continue to provide affordable and innovative medicines to a much wider population."
Edward Maggio, chief executive officer of Aegis, said: "Dr Reddy's has a worldwide reputation for developing innovative, high quality branded pharmaceuticals. We are pleased to be working with Dr Reddy's on this exciting application of our technology, another significant milestone in Aegis' commercialization strategy."
The products under the exclusive license agreement will be developed, manufactured and marketed worldwide by Dr Reddy's.